CRISPR/Cas9 for cancer treatment

• Verfasst von: Cheng, Xing [VerfasserIn]
• Verfasst von: Fan, Shaoyi [VerfasserIn]
• Verfasst von: Wen, Chengcai [VerfasserIn]
• Verfasst von: Du, Xianfa [VerfasserIn]
• Titel: CRISPR/Cas9 for cancer treatment
• Titelzusatz: technology, clinical applications and challenges
• Verf.angabe: Xing Chen, Shaoyi Fan, Chengcai Wen and Xianfa Du
• E-Jahr: 2020
• Jahr: 12 February 2020
• Umfang: 6 S.
• Fussnoten: Verlagskorrektur erschienen am 23. September 2020 mit dem DOI 10.1093/bfgp/elaa018 wegen falsch buchstabierten Namens für Herrn Xing Cheng ; Gesehen am 02.04.2022
• Titel Quelle: Enthalten in: Briefings in functional genomics
• Ort Quelle: Oxford : Oxford Univ. Press, 2010
• Jahr Quelle: 2020
• Band/Heft Quelle: 19(2020), 3, Seite 209-214
• ISSN Quelle: 2041-2657
• DOI: doi:10.1093/bfgp/elaa001
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1797404792

Abstract

Clustered regularly interspaced short palindromic repeats (CRISPR) is described as RNA mediated adaptive immune system defense, which is naturally found in bacteria and archaea. CRISPR-Cas9 has shown great promise for cancer treatment in cancer immunotherapy, manipulation of cancer genome and epigenome and elimination or inactivation of carcinogenic viral infections. However, many challenges remain to be addressed to increase its efficacy, including off-target effects, editing efficiency, fitness of edited cells, immune response and delivery methods. Here, we explain CRISPR-Cas classification and its general function mechanism for gene editing. Then, we summarize these preclinical CRISPR-Cas9-based therapeutic strategies against cancer. Moreover, the challenges and improvements of CRISPR-Cas9 clinical applications will be discussed.